Decoy Therapeutics (DCOY) Liabilities and Shareholders Equity (2014 - 2026)

Decoy Therapeutics (DCOY) has reported Liabilities and Shareholders Equity for 13 consecutive years, with $8.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 260.06% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $27.0 million (up 111.11% YoY), while the FY2025 annual figure was $11.1 million, up 265.76% from the prior year.
• Liabilities and Shareholders Equity declined to $8.4 million in Q1 2026 per DCOY's latest filing, from $11.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $35.5 million in Q1 2022 and bottomed at $1.4 million in Q2 2025.
• Historically, Liabilities and Shareholders Equity has averaged $10.9 million across 5 years, with a median of $8.4 million in 2023.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity sank 71.68% — and 2025, when it jumped 265.76%.
• Decoy Therapeutics' Liabilities and Shareholders Equity stood at $14.7 million in 2022, then sank by 55.04% to $6.6 million in 2023, then tumbled by 54.1% to $3.0 million in 2024, then surged by 265.76% to $11.1 million in 2025, then declined by 23.82% to $8.4 million in 2026.
• Business Quant data shows DCOY's Liabilities and Shareholders Equity at $8.4 million in Q1 2026, $11.1 million in Q4 2025, and $6.1 million in Q3 2025.